Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Biomarin Pharmaceuticals (BMRN)

Biomarin Pharmaceuticals (BMRN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 17,633,012
  • Shares Outstanding, K 185,474
  • Annual Sales, $ 1,846 M
  • Annual Income, $ -64,080 K
  • 60-Month Beta 0.33
  • Price/Sales 9.55
  • Price/Cash Flow 109.97
  • Price/Book 3.91
Trade BMRN with:

Options Overview Details

View History
  • Implied Volatility 32.11% ( -5.35%)
  • Historical Volatility 23.74%
  • IV Percentile 10%
  • IV Rank 13.95%
  • IV High 60.43% on 11/18/21
  • IV Low 27.52% on 08/30/21
  • Put/Call Vol Ratio 0.29
  • Today's Volume 381
  • Volume Avg (30-Day) 758
  • Put/Call OI Ratio 0.63
  • Today's Open Interest 27,601
  • Open Int (30-Day) 25,968

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate 0.12
  • Number of Estimates 8
  • High Estimate 0.17
  • Low Estimate 0.00
  • Prior Year -0.03
  • Growth Rate Est. (year over year) +500.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
84.33 +12.74%
on 07/20/22
97.76 -2.75%
on 08/08/22
+7.22 (+8.22%)
since 07/12/22
3-Month
70.73 +34.41%
on 06/14/22
97.76 -2.75%
on 08/08/22
+18.69 (+24.47%)
since 05/12/22
52-Week
70.73 +34.41%
on 06/14/22
97.76 -2.75%
on 08/08/22
+19.68 (+26.10%)
since 08/12/21

Most Recent Stories

More News
BIOMARIN INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of BioMarin Pharmaceutical Inc. - BMRN

/PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that...

BMRN : 95.07 (unch)
Aptinyx's (APTX) Mid-Stage Fibromyalgia Study Fails to Meet Goal

Aptinyx (APTX) reports disappointing data from a mid-stage study assessing NYX-2925 for the treatment of fibromyalgia. Stocks decline

BMRN : 95.07 (unch)
EPZM : 1.4700 (-1.34%)
APTX : 0.4060 (-32.33%)
INZY : 3.48 (+0.29%)
Roche (RHHBY) Influenza Drug Gets FDA Nod for Children

Roche (RHHBY) obtains FDA approval for expanded indication of influenza drug Xofluza.

RHHBY : 42.0000 (+2.34%)
DVAX : 16.34 (-2.10%)
BMRN : 95.07 (unch)
ALKS : 26.15 (+2.67%)
CRISPR Therapeutics (CRSP) Q2 Earnings & Sales Miss Estimates

CRISPR Therapeutics (CRSP) reports a wider-than-expected Q2 loss. Revenues also miss estimates.

BMRN : 95.07 (unch)
ALKS : 26.15 (+2.67%)
VRTX : 294.52 (+0.81%)
CRSP : 78.66 (+1.55%)
Clearwater Paper and Logitech International have been highlighted as Zacks Bull and Bear of the Day

Clearwater Paper and Logitech International are part of as Zacks Bull and Bear of the Day article.

XOM : 94.00 (+0.87%)
BMRN : 95.07 (unch)
LOGI : 59.13 (+1.97%)
CDNS : 188.83 (+1.33%)
CLW : 45.87 (+4.87%)
BioMarin's (BMRN) Q2 Earnings Top, Voxzogo Drives Sales

Biomarin Pharmaceutical's (BMRN) second-quarter earnings and sales beat estimates. BMRN slightly raises its sales guidance for the year.

SNY : 44.37 (+2.19%)
BMRN : 95.07 (unch)
DCPH : 16.41 (+4.06%)
BNTX : 160.35 (+1.11%)
BioMarin Pharmaceutical (BMRN) Q2 Earnings and Revenues Surpass Estimates

BioMarin (BMRN) delivered earnings and revenue surprises of 37.21% and 3.82%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

BMRN : 95.07 (unch)
CLDX : 37.33 (+8.11%)
Factors to Note Ahead of Humana (HUM) Q2 Earnings Release

Humana's (HUM) second-quarter results are likely to reflect higher premiums from the Retail segment and overall membership growth, partly offset by elevated technology-linked investments.

BMRN : 95.07 (unch)
HUM : 496.88 (+2.65%)
ALC : 70.07 (+0.73%)
DXCM : 89.83 (+1.80%)
BioMarin to Host Second Quarter 2022 Financial Results Conference Call and Webcast on Wednesday, August 3, at 4:30pm ET

/PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will...

BMRN : 95.07 (unch)
Novo Nordisk's (NVO) Haemophilia A Study Meets Safety Endpoint

Novo Nordisk's (NVO) phase I & II FRONTIER1 dose-escalation study investigating Mim8 for treating people with haemophilia A meets its primary safety endpoint.

BMRN : 95.07 (unch)
NVO : 107.50 (-1.19%)
LPTX : 1.2900 (-0.77%)
DTIL : 2.01 (+23.31%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

BioMarin Pharmaceutical Inc. focuses on the development and commercialization of treatments for serious life-threatening medical conditions, mostly for children. The company's portfolio comprises seven marketed products namely, Aldurazyme, Naglazyme, Kuvan a rare genetic enzyme deficiency disorder),...

See More

Key Turning Points

3rd Resistance Point 96.91
2nd Resistance Point 96.17
1st Resistance Point 95.62
Last Price 95.07
1st Support Level 94.33
2nd Support Level 93.59
3rd Support Level 93.04

See More

52-Week High 97.76
Last Price 95.07
Fibonacci 61.8% 87.43
Fibonacci 50% 84.25
Fibonacci 38.2% 81.06
52-Week Low 70.73

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar